Audit Report - in respect of Sharepro Services (India) Private Limited (Sharepro)
Cadila Healthcare Ltd has informed BSE regarding "Audit Report - in respect of Sharepro Services (India) Private Limited (Sharepro)".20-06-2016
20-06-2016
Zydus acquires two ANDAs from Teva, strengthens its US portfolio
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 20, 2016 titled "Zydus acquires two ANDAs from Teva, strengthens its US portfolio".20-06-2016
Zydus Cadila inks pact with Turkish firm
Healthcare provider Zydus Cadila, on Wednesday, announced the signing of a collaboration agreement with Turkey's Eczacibasi Ilac Pazarlama, A.S., to market biotech products in the Turkish market. T...15-06-2016
Zydus Cadila and Eczacibasi, a Turkish Healthcare Company, enter into a strategic collaboration to market biosimilars in Turkey
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 15, 2016, titled "Zydus Cadila and Eczacibasi, a Turkish Healthcare Company, enter into a strategic collaboration to market biosimilars in Turkey".15-06-2016
Buy Cadila Healthcare, target Rs 335-340: Siddarth Bhamre
The stock has fallen 3.6 per cent so far this calendar. It is trading at a P/E of 21.45. The stock is making an attempt to move above its 20-, 50- and 100-day moving averages14-06-2016
New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 11, 2016, titled "New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions."12-06-2016
Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 04, 2016 titled "Zydus receives approval from USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA"04-06-2016
Zydus Cadila gets final USFDA nod for Parkinson's treatment drug
Zydus Cadila has received final approval from the US health regulator to market Amantadine tablets, used for the treatment of Parkinson's disease and select viral infections, in the American market.T...01-06-2016
Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 01, 2016 titled "Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules".01-06-2016
Updates on Registrar & Share Transfer Agent
Cadila Healthcare Ltd has submitted to BSE a copy of Notice informing the shareholders regarding the appointment of M/s. Link Intime India Pvt Ltd as its Registrar & Share Transfer Agent with effective from June 01, 2016.31-05-2016